Pazopanib: therapeutic developments

Abstract

Pazopanib (Votrient, GW786034) is a potent pan-VEGF inhibitor in advanced clinical development. Like other orally available VEGFR inhibitors, pazopanib is clinically efficacious and well tolerated. The recently reported Phase III clinical trial in metastatic renal cell carcinoma showed activity similar to approved agents with variations in toxicity which has led to its recent FDA approval. Given the growing number of agents in this category, differences not only in single-agent activity but also toxicity and combinatorial potency will probably distinguish pazopanib from other similar agents.

Keywords::

• ovarian cancer
• pazopanib
• renal cell carcinoma
• soft tissue sarcoma
• tyrosine kinase inhibitor
• VEGFR

Notes